GRNA1599

**GRNA1599** appears to be an internal guide RNA component associated with nChroma Bio's chronic hepatitis B epigenetic editing program rather than a separately named standalone therapeutic product. Publicly available nChroma and ClinicalTrials.gov materials identify the clinical candidate as **CRMA-1001**, a liver-directed epigenetic editor delivered in a lipid nanoparticle and administered by intravenous infusion for chronic hepatitis B. CRMA-1001 is described as using an mRNA epigenetic editor construct plus a guide RNA to direct durable transcriptional silencing of both covalently closed circular HBV DNA and integrated HBV DNA by altering chromatin state and methylating viral DNA without genome cutting. Because the exact standalone identity, formulation, and development status of **GRNA1599** itself are not clearly disclosed in public sources, this entry treats it as a specific code-like component name linked to that platform, with limited confidence on whether it is an independently administered drug versus a subcomponent of CRMA-1001.